Passage BIO, Inc. (PASG) · Nov 19, 2026 · Other events

Passage Bio trial update shows 57% REM-422 response rate

Above the bar — 57% ORR at 24 mg; responses ongoing up to 19 months

Passage Bio’s clinical update highlights a 57% REM-422 response rate at the recommended Phase 2 dose, with responses lasting up to 19 months.

Passage Bio is being repositioned around Remix’s oncology pipeline. The company has wound down its gene-therapy programs and is moving toward completing its merger with Remix, whose lead asset is REM-422; Passage shareholders are expected to own only about 6% of the combined company, making this clinical program the substance of the new business story.

The update strengthens an already-positive clinical signal rather than creating one from scratch. Earlier public data had already shown activity in biomarker-positive ACC, but this filing raises the response rate at the recommended 24 mg dose to 57% and extends the observed response durability to 19 months. The sample remains very small—just 7 efficacy-evaluable biomarker-positive patients at the recommended dose—so the result is encouraging, not yet definitive.

MetricCurrent dataComparison
ORR at 24 mg (Key findings)57%4 of 7 patients
Partial responses, all doses (Key findings)1032 BM+ patients
Duration of response (Key findings)Up to 19 monthsMedian not reached
Time on treatment (Key findings)Up to 27 monthsOngoing
Median PFS, BM+ patients (Key findings)Not reachedBM−: 9 months
Phase 1 enrollment (Study update)69 patients60 efficacy-evaluable

The most important change is durability and patient selection. Median response duration and median progression-free survival have not yet been reached in biomarker-positive patients, while no objective responses were observed in biomarker-negative patients across tested doses. That sharp biomarker split supports a narrower but more credible precision-medicine story: REM-422 may work best in a defined MYB-positive population, rather than broadly across ACC. 〔0〕 〔1〕

The evidence still carries early-stage limitations. This is an open-label, non-randomized Phase 1/2 study, and one of the four responses at 24 mg was unconfirmed. The filing also says the potentially registrational Phase 2 study is expected to complete enrollment by year-end, so the next test is whether the signal holds in a larger, biomarker-selected cohort. 〔2〕

Bottom line: This is a meaningful upgrade to Remix’s lead-asset story, mainly because response durability is improving alongside a strong biomarker-defined response rate. It advances the combined company’s clinical narrative, but the small, early dataset keeps it a promising signal rather than a validated efficacy readout.

What to watch next

Phase 2 enrollment completion, expected by year-end

Original filing on SEC EDGAR

More Passage BIO, Inc. news

Passage Bio trial update shows 57% REM-422 response rate | PASG Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.